Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21(WAF1/CIP1) and p16(CDKN4)) in human prostate cancers

被引:53
作者
Gotoh, A
Kao, CH
Ko, SC
Hamada, K
Liu, TJ
Chung, LWK
机构
[1] UNIV VIRGINIA,SCH MED,DEPT UROL,MOL UROL & THERAPEUT PROGRAM,CHARLOTTESVILLE,VA 22908
[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC & CARDIOVASC SURG,SECT THORAC MOL ONCOL,HOUSTON,TX
[3] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030
关键词
gene therapy; tumor suppressor gene; p53; p21(WAF1/CIP1); p16(CDKN2);
D O I
10.1016/S0022-5347(01)64574-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Overexpressing or restoring the basal levels of tumor suppressor genes in cancer cells can suppress tumorigenicity of cancer cells. In this communication, we compared tumor suppressive activities of three well-defined tumor suppressive genes (p53, p21(WAF1/CIP1), and p16(CDKN2)) delivered individually to prostate cancer cells with adenoviral vector (Ad). Materials and Methods: Efficacy of growth inhibition by recombinant adenoviruses bearing p53, p21(WAF1/CIP1), or p16(CDKN2) (Ad5CMV-p53, Ad5CMV-p21, Ad5CMV-p16) genes were tested in vitro on androgen-dependent (LNCaP) and androgen-independent (C4-2, DU-145, and PC-3) human prostate cancer cells, ex vivo and in vivo on PC-3 tumor. Results: Ad5CMV-p53 was observed to exert the greatest growth inhibitory action on all of the cell lines tested; inhibition appeared to be cytolytic. In comparison to control Ad5CMV-PA added samples, the growth inhibitory action of Ad5CMV-p21 and Ad5CMV-p16 appeared to be cytostatic. Ad5CMV-p53 is more effective than Ad5CMV-p16 and Ad5CMV-p21 in inhibiting the tumor ''take'' rate. A similar order of antitumor activity was observed when recombinant adenoviruses were injected intratumorily to previously established PC-3 tumors in vivo. Conclusion: p53 is the most effective tumor suppressor gene to target human prostate cancer.
引用
收藏
页码:636 / 641
页数:6
相关论文
共 43 条
  • [1] PACKAGING CAPACITY AND STABILITY OF HUMAN ADENOVIRUS TYPE-5 VECTORS
    BETT, AJ
    PREVEC, L
    GRAHAM, FL
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (10) : 5911 - 5921
  • [2] FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA
    CALDAS, C
    HAHN, SA
    DACOSTA, LT
    REDSTON, MS
    SCHUTTE, M
    SEYMOUR, AB
    WEINSTEIN, CL
    HRUBAN, RH
    YEO, CJ
    KERN, SE
    [J]. NATURE GENETICS, 1994, 8 (01) : 27 - 32
  • [3] GENETIC MECHANISMS OF TUMOR SUPPRESSION BY THE HUMAN P53 GENE
    CHEN, PL
    CHEN, YM
    BOOKSTEIN, R
    LEE, WH
    [J]. SCIENCE, 1990, 250 (4987) : 1576 - 1580
  • [4] P53 FUNCTIONS AS A CELL-CYCLE CONTROL PROTEIN IN OSTEOSARCOMAS
    DILLER, L
    KASSEL, J
    NELSON, CE
    GRYKA, MA
    LITWAK, G
    GEBHARDT, M
    BRESSAC, B
    OZTURK, M
    BAKER, SJ
    VOGELSTEIN, B
    FRIEND, SH
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (11) : 5772 - 5781
  • [5] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [6] WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO
    FARMER, G
    BARGONETTI, J
    ZHU, H
    FRIEDMAN, P
    PRYWES, R
    PRIVES, C
    [J]. NATURE, 1992, 358 (6381) : 83 - 86
  • [7] Hepatocellular carcinoma and p53 gene therapy
    Fricker, J
    [J]. MOLECULAR MEDICINE TODAY, 1996, 2 (09): : 361 - 361
  • [8] A TRANSCRIPTIONALLY ACTIVE DNA-BINDING SITE FOR HUMAN P53 PROTEIN COMPLEXES
    FUNK, WD
    PAK, DT
    KARAS, RH
    WRIGHT, WE
    SHAY, JW
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (06) : 2866 - 2871
  • [9] GRAVIELI Y, 1992, J CELL BIOL, V119, P493
  • [10] Huggins C, 1941, CANCER RES, V1, P293